



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



ENPP1 (human, recombinant)

Item No. 33397

Overview and Properties

Synonyms: CD203a, Ectonucleotide Pyrophosphatase/Phosphodiesterase 1, Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 1, Membrane Component Chromosome 6 Surface Marker 1, PDNP1, Plasma Cell Membrane Glycoprotein PC-1

Source: Active C-terminal 10x-His-tagged human ENPP1 expressed in HEK293 cells

Amino Acids: 107-925

Uniprot No.: P22413

Molecular Weight: 98.7 kDa

Storage: -80°C (as supplied)

Stability: ≥1 year

Purity: *batch specific* (≥90% estimated by SDS-PAGE)

Supplied in: TBS, pH 7.4, with 5% glycerol

Protein Concentration: *batch specific* mg/ml


Activity: *batch specific* U/ml

Specific Activity: *batch specific* U/mg

Unit Definition: One unit is defined as the amount of enzyme required to produce 1 nmol of *p*-nitrophenol (*p*NP) per minute at 25°C in 100 mM Tris, pH 9.0, with 150 mM sodium chloride, and 1 mM *p*NP-TMP.


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images




Lane 1: MW Markers
Lane 2: ENPP1 (2 µg)
Lane 3: ENPP1 (4 µg)

SDS-PAGE Analysis of ENPP1.



ENPP1 activity was determined by measuring the hydrolysis of thymidine monophosphate *p*-nitrophenol (TMP-*p*NP). Production of the *p*-nitrophenol is measured by monitoring the increase in absorbance at 405 nm.



ENPP1 initial rate with and without 30 µM ENPP1 Inhibitor C (Item No. 29809).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/04/2022

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) is a type II transmembrane glycoprotein with nucleotide pyrophosphatase and phosphodiesterase enzyme activities.¹ It is expressed in skeletal, adipose, hepatic, renal, cardiac, and placental tissues, as well as pancreatic islets, salivary glands, chondrocytes, fibroblasts, and lymphocytes.² ENPP1 is a critical regulator of purinergic signaling that catalyzes the hydrolysis of ATP or GTP to AMP or GMP, respectively, as well as the hydrolysis of cGAMP, and has roles in platelet aggregation, muscle contraction, hypoxia, ischemia, cGAS-STING signaling, and cell proliferation, migration, apoptosis, and differentiation.^{1,3} This nucleotide hydrolysis also generates inorganic pyrophosphates, which inhibit bone and cartilage mineralization, implicating ENPP1 as a regulator of bone and cartilage development. Loss-of-function mutations in *ENPP1* are associated with various calcification-related disorders, including autosomal recessive hypophosphatemic rickets type 2 (ARHR2) generalized arterial calcification of infancy (GACI), and pseudoxanthoma elasticum (PXE).^{1,4} *ENPP1* SNPs are associated with insulin resistance and the development of diabetic nephropathy.^{2,5} ENPP1 hydrolysis of cGAMP in the tumor microenvironment decreases STING activation, facilitates immunosuppression, and is associated with enhanced bone metastasis in mouse xenograft models of breast cancer.^{1,3} Inhibition of ENPP1 promotes STING activation and increases survival in various mouse xenograft models.¹ Cayman's ENPP1 (human, recombinant) protein can be used for enzyme activity assays.

References

1. Onyedibe, K.I., Wang, M., and Sintim, H.O. ENPP1, an old enzyme with new functions, and small molecule inhibitors - A STING in the tale of ENPP1. *Molecules* **24**(22), E4192 (2019).
2. Sortica, D.A., Crispim, D., Zaffari, G.P., *et al.* The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy. *Arq. Bras. Endocrinol. Metab.* **55**(9), 677-685 (2011).
3. Li, L., Yin, Q., Kuss, P., *et al.* Hydrolysis of 2'3'-cGAMP by ENPP1 and design of nonhydrolyzable analogs. *Nat. Chem. Biol.* **10**(12), 1043-1048 (2014).
4. Bowman, M.A.H. and McNally, E.M. Genetic pathways of vascular calcification. *Trends Cardiovasc. Med.* **22**(4), 93-98 (2012).
5. Bacci, S., De Cosmo, S., Prudente, S., *et al.* ENPP1 gene, insulin resistance and related clinical outcomes. *Curr. Opin. Clin. Nutr. Metab. Care* **10**(4), 403-409 (2007).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM